Member Info for David1951c

Questions

Presumably the update and timelines for the Roche and Genetech collaborations will be included.

Possibly a more direct question is whether the Board see the need to raise funds to complete or accelerate the work under way and to support the additional collaborations expected in the coming months.

SP also dropped from 0.86 to 0.175 in April! Held this for some years so pleased to see not selling may turn out to be a good decision after all.

With so much going on next news could come at any time. Results on Roche collaboration due by end of November. New contracts could come at any time. Re-reading 6 October announcement gives reassurance that ONC are on course for greater things and an increased SP in next six months.

On AIM it is quite common for SP to gradually fall back from a spike up and after a placing. For PIs that trade it gives a good opportunity to sell and buy back at a lower SP. It is unfortunate and frustrating for holders but with its not fit for purpose pricing methods, AIM favours traders. That is one reason why negative posters inhabit these BBs. Occasionally good news comes more quickly and traders may lose out but many times it works. They have little interest in the company or their work to benefit society.
Unfortunately I expect further drift in SNG until more news directly or indirectly. It is easier for LTHs with low averages like me but harder for anyone buying at the top. So we need more news to keep or increase the SP. This is not a deramp. I have been in SNG and Avacta since 2017 as well as numerous other AIM stocks. These are my largest two holdings.
I believe in both companies and what they are doing.

In both Faron and SNG. Quite different.

With no information on the value of the new contracts it is not possible to value the company. Five new contracts and 100% renewals is very good news but I would not add until the future revenue streams and funding are clearer. Half year revenue £0.54m and loss £1.17m are not that inspiring although with £4m cash after July fund raise there should be enough in the bank for 2021.

Above all reading the details shows that SNG have the ambition and means to become a much bigger company and SP could be multiples if trials are successful and production levels can be ramped up with partners. They could go it alone but it is much more likely that major pharmas will now show an interest because of the wider value of treatments beyond covid. Obviously this hurts those who have paid more than 175p in the short term but I suspect this could close tomorrow nearer to 200p. If not and you believe in the company, just buy what you can at price available.

FOG was probably the first individual share I bought some years when I retired - 50k @7.7 p. Beetaloo seemed a massive prospect and I bought more over the years with now an average of 13.65p. I am a small investor and did not overstretch while I was learning. It now looks as though patience is paying off. Anyway great to see and brilliant news for bigger investors especially with O&G having been in the doldrums.

The partisan Align note has a 35p target for 2022 but this was written before the opportunity to get 100% ownership. The reward potential is huge but some risks remain. It is worth reading the Align note for info and facts of the mines and prospects and to critique their target price assessment. Importantly production is near term and in a safer jurisdiction than many small gold plays on AIM.

Only 5% rise is due to small volume and low demand. Hard to explain that given the news already released and a lot more to come. The upside is there is not too much volatility as seen on many others in the pharma sector.
ONC are working with some first class companies as well for Government (with MDC) and the latest with Cedars. There is very little information on the value of these collaborations but with the growing number - more to be announced - the potential is there for the coming months. ONC looks a promising investment but will not be a runaway train! For holders it is an opportunity to add when funds allow.

More good news and I feel very positive having added in last week. As usual there is no financial information (commercial sensitivity) but it can only add to income stream which should be building significantly.

Expert should produce WITHIN 30 days so hopefully it will be less than that given the established valuation methodology. Also news could come on mining and environmental subsidies available that were mentioned a few months ago.

Trek,
Thanks for the posts and comments. I am surprised there is not more interest in ONC but it gives the opportunity to buy more shares (latest 5k buy today shown as a sell as happened yesterday). Mcap around £100m with the number and quality of collaborations growing ONC is quietly moving ahead. There is also much less SP volatility which bedevils other holdings. I will buy more but don't want to sell any of largest holdings in Avacta or SNG yet as they also have more news coming. Sorry to see 4D slipped today but I will look at that again.

Trek,
More news came more quickly than expected. Interesting to see what happens and whether this RNS creates much more interest and more commentators. It used to be like this on Avacta, SNG and VAL boards but most comments on those now are not worth anything.

Hopefully this is a major step forward for the development and application of diagnoses, treatments and vaccines in Covid and then many other areas to help many people to a better outcome. I wish I better understood the science but it sounds very significant. With more news to come on Roche collaborations as well as early lung CDT, the future is bright, most importantly for patients.

The huge SP rise and drop with large other daily movements sometimes on small volumes confirms AIM pricing methodology is not fit for purpose. It must be incredibly frustrating for the CEO and Board (as well as LTHs) in trying to bring the companies together. Value of the company and therefore Mcap should not vary like this. Many LTHs who built holdings at the lows will be in profit and less concerned about the daily movement. With the potential for the combined company it requires patience and with more news in the pipeline, hopefully a sustained rise will be possible.

An industry leader would surely only collaborate with Eqtec if they were satisfied that they have the a product and implementation that will benefit them too. Very positive news and reasonable timetable to move this forward with many potential clients.

28p is 60% down. Investors should have some maths capability! This is AIM and the SP of 70p was a ridiculous spike that showed the pricing methods are not fit for purpose.

just seen two. I bought 5,000 more at 49.99 but shown as a sell. Hard to tell if bottom reached.

Trek,
Comments appreciated and it all looks promising. This company seems to be low profile compared to peers but has a lot of potential based on current Mcap and their pipeline. Hopefully ONC are on the cusp of greater success.
In looking at micro pharmas have you any other targets - mine is N4.